These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31168673)

  • 1. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
    de Groot M; Aronica E; Heimans JJ; Reijneveld JC
    Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.
    Bedetti C; Romoli M; Maschio M; Di Bonaventura C; Nardi Cesarini E; Eusebi P; Siliquini S; Dispenza S; Calabresi P; Costa C
    Eur J Neurol; 2017 Oct; 24(10):1283-1289. PubMed ID: 28796376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.
    Romoli M; Perucca E; Sen A
    Epilepsy Behav; 2020 Feb; 103(Pt A):106861. PubMed ID: 31917143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.
    Wu PP; Cao BR; Tian FY; Gao ZB
    Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
    Talos DM; Chang M; Kosaras B; Fitzgerald E; Murphy A; Folkerth RD; Jensen FE
    Pediatr Res; 2013 Jan; 73(1):24-30. PubMed ID: 23138400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
    Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
    Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
    Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
    Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.